Travere Therapeutics, Inc.
No enriched coverage for $TVTX in the last 7 days.
LYONS GARY A sold 10,000 shares of Travere Therapeutics, Inc. (TVTX) at an average of $63.28 ($62.53–$64.16, $0.63M total) across 5 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.
A dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.
Simply Wall St discusses Travere Therapeutics (TVTX) Q2 2026 results. Revenue rose to $169.58M from $114.45M, while net loss widened to $34.8M and basic loss per share to $0.37. The company cited record demand for FILSPARI in IgA nephropathy and an early FSGS launch, plus pipeline progress via civorebrutinib in-licensing and HARMONY pegtibatinase.
Recent TVTX coverage spans earnings, insider activity and corporate actions.
In the last 30 days, TVTX insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($633K). The most active reporter was LYONS GARY A with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Potential negative signal as a director reduces stake, may pressure short-term price.
TVTX’s move is presented as earnings-related, which can support momentum trades but lacks detail here.
FILSPARI demand is strengthening top-line, but widening losses and cash-burn risk likely keep valuation and near-term sentiment fragile.
The earnings beat and sharp jump in FILSPARI sales are the primary catalyst behind the reported after-hours rally, despite a wider EPS and net loss.
Strong commercial momentum for FILSPARI and updated pipeline milestones (HARMONY Phase 3 topline expected in 2H 2027) support a constructive near-to-medium term risk view, despite higher operating expenses and a larger SG&A base.
alphai scores every news story that mentions TVTX with an AI model for sentiment and relevance, and aggregates insider trades from Travere Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
LYONS GARY A sold 10,000 shares of Travere Therapeutics, Inc. (TVTX) at an average of $63.28 ($62.53–$64.16, $0.63M total) across 5 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.
1 min readA dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.
4 min readSimply Wall St discusses Travere Therapeutics (TVTX) Q2 2026 results. Revenue rose to $169.58M from $114.45M, while net loss widened to $34.8M and basic loss per share to $0.37. The company cited record demand for FILSPARI in IgA nephropathy and an early FSGS launch, plus pipeline progress via civorebrutinib in-licensing and HARMONY pegtibatinase.
6 min readTravere Therapeutics (TVTX) shares rose more than 13% after hours after results for the quarter ended June 30. Total revenue was $169.58 million, above analysts’ $159.32 million estimate. U.S. net product sales rose to $161.4 million, with FILSPARI at $141.1 million. EPS was a loss of $0.10 versus a $0.23 estimate.
4 min readTravere Therapeutics, Inc. (TVTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.com mediarelations@travere.com Travere Therapeutics Reports Second Quarter 2026 Financial Results Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during
6 min readTravere Therapeutics, Inc. (TVTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. tvtx-20260706 0001438533 false 0001438533 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K ___________________________ Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of
2 min readEverest Medicines (1952.HK) said it closed an exclusive licensing and collaboration deal with Travere Therapeutics (TVTX) for civorebrutinib (EVER001) in the U.S. and global markets excluding Greater China and parts of East and Southeast Asia. Everest will receive $112.5M upfront and up to about $1.03B in milestone payments, plus tiered royalties.
2 min readEverest Medicines (HKEX:1952) said it closed an exclusive licensing and collaboration deal with Travere Therapeutics (NASDAQ:TVTX) for civorebrutinib (EVER001) in the U.S. and global markets excluding Greater China and parts of East/Southeast Asia. Everest will receive $112.5M upfront, plus up to ~$1.03B in milestone payments and tiered royalties on sales.
4 min readCoughlin Timothy sold 10,000 shares of Travere Therapeutics, Inc. (TVTX) at $50.07 ($0.50M total) on 2026-06-12 under a Rule 10b5-1 trading plan.
1 min readTravere Therapeutics, Inc. (TVTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. tvtx-20260612 0001438533 false 0001438533 2026-06-12 2026-06-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 8-K ___________________________ Current Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of
2 min read
